

Guo

Am J Cardiol 2017;119:585e593

Fixed-effects pairwise meta-analysis

Outcome	Placebo vs. Warfarin	Rivaroxaban vs. Warfarin	Apixaban vs. Warfarin	Edoxaban vs. Warfarin	Dabigatran vs. Warfarin
Vascular Events	1.74 (0.57, 16.02)	0.62 (0.37, 1.71)	0.84 (0.74, 0.95)	0.97 (0.59, 1.50)	0.51 (0.29, 1.44)
Stroke	1.58 (1.22, 2.06)	0.75 (0.66, 0.85)	0.67 (0.49, 0.92)	1.94 (0.26, 14.70)	0.80 (0.70, 0.92)
Mortality	1.10 (0.80, 1.53)	0.83 (0.70, 1.00)	0.91 (0.85, 0.97)	0.90 (0.83, 0.98)	0.78 (0.61, 1.00)
Hemorrhage Events	0.59 (0.28, 1.23)	0.79 (0.62, 0.99)	0.67 (0.47, 0.95)	0.59 (0.31, 1.14)	0.40 (0.20, 0.82)
Myocardial Infarction	2.24 (0.44, 11.49)	0.87 (0.66, 1.16)	0.90 (0.68, 1.18)	0.90 (0.52, 1.56)	0.72 (0.19, 2.63)

Lip

Int Journal Card 204 (2016) 88–94

Supplementary table 3: Fixed-effects NMA results for main outcomes of interest (NOACs vs warfarin)

Treatment comparison	Outcome, HR (95% CrI) ^a									
	Efficacy						Safety			
	Stroke + SE	All-cause mortality	Fatal stroke	MI	Haemorrhagic stroke	Ischaemic stroke	Major bleeding	GI bleeding	ICH	Total discontinuations
Apixaban vs. Warfarin	0.79 (0.66, 0.95)	0.89 (0.80, 1)	0.63 (0.43, 0.93)	0.87 (0.65, 1.16)	0.51 (0.35, 0.74)	0.96 (0.76, 1.20)	0.69 (0.60, 0.80)	0.89 (0.68, 1.15)	0.41 (0.30, 0.57)	0.91 (0.86, 0.96)
Rivaroxaban vs. Warfarin	0.87 (0.74, 1.03)	0.92 (0.82, 1.03)	0.71 (0.49, 1.03)	0.92 (0.73, 1.16)	0.59 (0.39, 0.89)	0.99 (0.82, 1.19)	1.05 (0.91, 1.2)	1.46 (1.19, 1.79)	0.71 (0.50, 0.99)	1.08 (1.01, 1.15)
Dabigatran 110mg BD vs. Warfarin	0.90 (0.74, 1.10)	0.91 (0.80, 1.03)	0.67 (0.42, 1.06)	1.28 (0.95, 1.74)	0.31 (0.16, 0.55)	1.12 (0.89, 1.42)	0.80 (0.70, 0.93)	1.07 (0.84, 1.37)	0.30 (0.19, 0.45)	1.32 (1.21, 1.44)
Dabigatran 150mg BD vs. Warfarin	0.65 (0.52, 0.81)	0.88 (0.77, 1)	0.51 (0.30, 0.84)	1.26 (0.93, 1.71)	0.26 (0.13, 0.48)	0.75 (0.58, 0.97)	0.93 (0.81, 1.07)	1.46 (1.16, 1.83)	0.42 (0.28, 0.60)	1.37 (1.26, 1.50)
Edoxaban 30mg vs. Warfarin	1.13 (0.98, 1.31)	0.87 (0.79, 0.97)	0.84 (0.62, 1.15)	1.19 (0.95, 1.48)	0.34 (0.22, 0.50)	1.42 (1.20, 1.68)	0.47 (0.40, 0.55)	0.67 (0.53, 0.83)	0.30 (0.21, 0.43)	0.95 (0.89, 1)
Edoxaban 60mg vs. Warfarin	0.87 (0.75, 1.02)	0.92 (0.83, 1.01)	0.93 (0.68, 1.26)	0.93 (0.73, 1.18)	0.55 (0.39, 0.78)	1.00 (0.84, 1.20)	0.80 (0.71, 0.91)	1.23 (1.02, 1.49)	0.46 (0.34, 0.62)	1.00 (0.95, 1.06)

Supplementary table 4: Fixed-effects NMA for additional outcomes of interest (NOAC vs warfarin and NOAC vs NOAC).

Treatment comparison	Outcome, HR (95% CrI) ^a			
	Efficacy		Safety	
	Any stroke	Systemic embolism	CRNM bleeding ^b	'Other' major bleed ^c
Apixaban vs. Warfarin	0.79 (0.65, 0.95)	0.90 (0.44, 1.80)	0.68 (0.59, 0.79)	0.81 (0.69, 0.95)
Rivaroxaban vs. Warfarin	0.91 (0.78, 1.08)	0.76 (0.43, 1.33)	1.04 (0.95, 1.12)	1.13 (0.97, 1.32)
Dabigatran 110mg BD vs. Warfarin	0.64 (0.51, 0.80)	0.70 (0.35, 1.36)	-	0.95 (0.81, 1.11)
Dabigatran 150mg BD vs. Warfarin	0.91 (0.74, 1.12)	0.64 (0.31, 1.26)	-	1.08 (0.93, 1.26)
Edoxaban 30mg vs. Warfarin	1.13 (0.97, 1.32)	1.25 (0.73, 2.19)	0.65 (0.60, 0.71)	0.53 (0.45, 0.63)
Edoxaban 60mg vs. Warfarin	0.88 (0.75, 1.04)	0.66 (0.34, 1.26)	0.85 (0.79, 0.92)	0.91 (0.79, 1.05)
Apixaban vs. Rivaroxaban	0.86 (0.67, 1.10)	1.19 (0.48, 2.93)	0.66 (0.55, 0.78)	0.71 (0.57, 0.89)
Apixaban vs. Dabigatran 110mg BD	1.24 (0.92, 1.66)	1.29 (0.48, 3.43)	-	0.85 (0.68, 1.06)
Apixaban vs. Dabigatran 150mg BD	0.87 (0.66, 1.15)	1.41 (0.52, 3.87)	-	0.75 (0.60, 0.93)
Apixaban vs. Edoxaban 30mg	0.70 (0.55, 0.89)	0.72 (0.29, 1.75)	1.05 (0.88, 1.24)	1.51 (1.20, 1.90)
Apixaban vs. Edoxaban 60mg	0.89 (0.70, 1.15)	1.37 (0.51, 3.60)	0.80 (0.67, 0.94)	0.89 (0.72, 1.1)
Dabigatran 110mg BD vs. Rivaroxaban	0.70 (0.53, 0.92)	0.93 (0.38, 2.22)	-	0.84 (0.67, 1.04)
Dabigatran 150mg BD vs. Rivaroxaban	0.99 (0.76, 1.29)	0.84 (0.34, 2.06)	-	0.95 (0.77, 1.19)
Edoxaban 30mg vs. Rivaroxaban	1.24 (0.99, 1.55)	1.66 (0.76, 3.67)	0.63 (0.56, 0.70)	0.47 (0.37, 0.59)
Edoxaban 60mg vs. Rivaroxaban	0.96 (0.77, 1.21)	0.87 (0.36, 2.08)	0.82 (0.74, 0.92)	0.8 (0.65, 0.99)
Dabigatran 150mg BD vs. Dabigatran 110mg BD	0.70 (0.55, 0.88)	0.91 (0.42, 1.94)	-	1.00 (0.98, 1.33)
Edoxaban 30mg vs. Dabigatran 110mg BD	1.77 (1.35, 2.34)	1.80 (0.76, 4.32)	-	0.56 (0.45, 0.70)

Summary of results from Network Meta-analysis for All-cause Stroke or Systemic Embolism

Treatment	Pair-wise Meta- Analysis, OR (95% CI) versus standard adjusted dose VKA	NMA, Odds Ratio (95% CrI) versus standard adjusted dose VKA	NMA, Absolute Risk Difference per 1,000 treated (95% CrI) versus standard adjusted dose VKA	Probability Best (%) for Outcome	Rank for Outcome	SUCRA
Dabigatran 150 mg twice daily	0.66(0.53,0.82)	0.66 (0.53,0.82)	6 fewer (8 fewer-3 fewer)	85.2%	12	98.1%
Apixaban 5 mg twice daily	0.79(0.66,0.94)	0.78 (0.65,0.94)	4 fewer (6 fewer-1 fewer)	11.2%	25	85.4%
Edoxaban 60 mg daily	0.87(0.71,1.05)	0.87 (0.74,1.01)	3 fewer (5 fewer-1 more)	1.2%	37	72.8%
Rivaroxaban 20 mg daily	0.88(0.74,1.05)	0.87 (0.74,1.03)	3 fewer (5 fewer-1 more)	1.0%	39	71.2%
Dabigatran 110 mg twice daily	0.91(0.75,1.11)	0.91 (0.74,1.12)	2 fewer (5 fewer-2 more)	0.1%	45	64.7%
Standard Adjusted- Dose VKA	NA	NA	NA	0.0%	60	50.2%
Edoxaban 30 mg daily	1.14(0.94,1.37)	1.14 (0.98,1.32)	3 more (1 fewer-6 more)	0.0%	74	36.5%
Medium Dose Aspirin (> 100 mg and ≤ 300 mg daily)	1.21(0.51,2.87)	1.35 (0.74,2.47)	6 more (5 fewer-24 more)	1.2%	78	32.0%
No treatment/Placebo	1.84(0.66,5.1)	1.53 (0.9,2.63)	9 more (2 fewer-26 more)	0.1%	89	21.5%
Low Dose Aspirin (≤ 100 mg daily)	2.03(1.32,3.12)	1.87 (1.26,2.8)	14 more (5 more-29 more)	0.0%	101	9.4%
Clopidogrel 75 mg OD & Low dose Aspirin (≤ 100 mg daily)	1.93(1.41,2.64)	1.93 (1.42,2.65)	15 more (7 more-26 more)	0.0%	102	8.3%

Summary of results from Network Meta-analysis for Major Bleeding

Treatment	Pair-wise Meta- Analysis, OR (95% CI) versus standard adjusted dose VKA	NMA, Odds Ratio (95% CrI) versus standard adjusted dose VKA	NMA, Absolute Risk Difference per 1,000 treated (95% CrI) versus standard adjusted dose VKA	Probability Best (%) for Outcome	Rank for Outcome	SUCRA
Edoxaban 30 mg daily	0.46(0.39,0.55)	0.46(0.4,0.54)	18 fewer (20 fewer-15 fewer)	29.7%	17	92.9%
No treatment/Placebo	0.39(0.08,2.02)	0.33(0.08,1.08)	22 fewer (31 fewer-3 more)	70.2%	17	92.6%
Apixaban 5 mg twice daily	0.69(0.60,0.80)	0.69(0.6,0.8)	10 fewer (13 fewer-7 fewer)	0.0%	32	78.1%
Edoxaban 60 mg daily	0.78(0.67,0.92)	0.79(0.69,0.9)	7 fewer (10 fewer-4 fewer)	0.0%	45	64.6%
Dabigatran 110 mg twice daily	0.8(0.68,0.94)	0.8(0.69,0.93)	7 fewer (10 fewer-3 fewer)	0.0%	47	62.7%
Dabigatran 150 mg twice daily	0.93(0.81,1.07)	0.93(0.8,1.08)	3 fewer (7 fewer-3 more)	0.0%	68	41.7%
Low Dose Aspirin (\leq 100 mg daily)	1.01(0.57,1.78)	1.05(0.6,1.86)	2 more (13 fewer-26 more)	0.1%	79	30.6%
Standard Adjusted- Dose VKA	NA	NA	NA	0.0%	80	30.2%
Rivaroxaban 20 mg daily	1.03(0.9,1.18)	1.03(0.89,1.18)	1 more (4 fewer-6 more)	0.0%	84	26.3%
Clopidogrel 75 mg OD & Low dose Aspirin (\leq 100 mg daily)	1.1(0.82,1.48)	1.1(0.83,1.47)	4 more (6 fewer-15 more)	0.0%	89	20.8%
Medium Dose Aspirin (> 100 mg and \leq 300 mg daily)	1.68(0.50,5.69)	1.79(0.63,5.67)	24 more (12 fewer-120 more)	0.0%	100	9.8%

Sun

JAMA Ophthalmol 2017;135(8):864-870

Intraocular bleeding vs warfarin, fixed effects meta-analysis

	RR (95% CI)
Apixaban	1,37 (0,77-2,43)
Rivaroxaban	0,82 (0,47-1,43)
Edoxaban	0,60 (0,39-0,92)
Dabigatran	0,72 (0,61-0,99)